Bcl-2 Family Proteins as Therapeutic Targets

ArticleinCurrent pharmaceutical design 16(28):3132-48 · September 2010with10 Reads
Impact Factor: 3.45 · DOI: 10.2174/138161210793292429 · Source: PubMed

    Abstract

    The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.